Rifabutin Disease Interactions
There are 3 disease interactions with rifabutin:
Antibiotics (Includes Rifabutin) ↔ Colitis
Severe Potential Hazard, Low plausibility
Applies to: Colitis/Enteritis (Noninfectious)
Pseudomembranous colitis has been reported with most antibacterial agents and may range in severity from mild to life-threatening, with an onset of up to several weeks following cessation of therapy. Antibiotic therapy can alter the normal flora of the colon and permit overgrowth of Clostridium difficile, whose toxin is believed to be a primary cause of antibiotic-associated colitis. The colitis is usually characterized by severe, persistent diarrhea and severe abdominal cramps, and may be associated with the passage of blood and mucus. The most common culprits are clindamycin, lincomycin, the aminopenicillins (amoxicillin, ampicillin), and the cephalosporins. Therapy with broad-spectrum antibiotics and other agents with significant antibacterial activity should be administered cautiously in patients with a history of gastrointestinal diseases, particularly colitis. There is some evidence that pseudomembranous colitis, if it occurs, may run a more severe course in these patients and that it may be associated with flares in their underlying disease activity. The offending antibiotic(s) should be discontinued if significant diarrhea occurs during therapy. Stool cultures for Clostridium difficile and stool assay for C. difficile toxin may be helpful diagnostically. A large bowel endoscopy may be considered to establish a definitive diagnosis in cases of severe diarrhea.
Rifabutin (Includes Rifabutin) ↔ Tb
Severe Potential Hazard, High plausibility
Applies to: Tuberculosis -- Active
Rifabutin should not be given as monotherapy in patients with active tuberculosis (TB). The administration of rifabutin in the absence of appropriate antituberculous agents may induce organisms resistant to rifabutin and other rifamycins, including rifampin and rifapentine. Likewise, patients must not have active TB when receiving rifabutin therapy for Mycobacterium avium complex prophylaxis or other indications where rifabutin might be used alone. Patients who develop symptoms consistent with active TB during rifabutin therapy should be evaluated promptly so that an effective antituberculosis regimen may be instituted if necessary.
Rifabutin (Includes Rifabutin) ↔ Neutropenia/Thrombocytopenia
Moderate Potential Hazard, Moderate plausibility
Applies to: Neutropenia, Thrombocytopenia
Rifabutin may occasionally cause neutropenia and rarely, thrombocytopenia. Patients with preexisting neutropenia and/or thrombocytopenia should be monitored closely during rifabutin therapy for further decreases in blood counts, and therapy discontinued if appropriate.
You should also know about...
rifabutin drug Interactions
There are 334 drug interactions with rifabutin
See also...
Drug Interaction Classification
The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
